Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AVIR

Atea Pharmaceuticals Inc

Dec 13 • 04:00PM ET

2.93

Dollar change -0.02
Percentage change -0.68	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA GILD BNTX JNJ NVAX VXRT RIGL PTGX CYCN

| Held by: VTI IWM VXF IWN IBB VTWO SCHA VHT IWC PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.07	Insider Own	12.32%	Shs Outstand	84.46M	Perf Week	-0.34%
Market Cap	245.80M	Forward P/E	-	EPS next Y	-1.58	Insider Trans	-4.04%	Shs Float	74.06M	Perf Month	-12.54%
Income	-174.01M	PEG	-	EPS next Q	-0.29	Inst Own	65.83%	Short Float	3.52%	Perf Quarter	-24.68%
Sales	0.00M	P/S	-	EPS this Y	-10.74%	Inst Trans	2.72%	Short Ratio	11.51	Perf Half Y	-18.84%
Book/sh	5.43	P/B	0.54	EPS next Y	12.41%	ROA	-31.67%	Short Interest	2.61M	Perf Year	-6.09%
Cash/sh	5.76	P/C	0.51	EPS next 5Y	-	ROE	-33.45%	52W Range	2.75 - 4.60	Perf YTD	-3.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-71.56%	ROI	-37.86%	52W High	-36.30%	Beta	0.21
Dividend TTM	-	Quick Ratio	19.33	Sales past 5Y	104.50%	Gross Margin	-	52W Low	6.55%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	19.33	EPS Y/Y TTM	-31.62%	Oper. Margin	-	RSI (14)	36.46	Volatility	5.88% 4.79%
Employees	75	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	2.50	Target Price	6.20
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	7.15%	Payout	-	Rel Volume	1.13	Prev Close	2.95
Sales Surprise	-	EPS Surprise	13.29%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	226.57K	Price	2.93
SMA20	-7.94%	SMA50	-12.34%	SMA200	-19.09%	Trades		Volume	256,573	Change	-0.68%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$2 → $6.88
Aug-10-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$14 → $7
Nov-18-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-20-21	Downgrade	JP Morgan	Overweight → Neutral	$61 → $16
Oct-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$55
Nov-25-20	Initiated	Evercore ISI	Outperform
Nov-24-20	Initiated	William Blair	Outperform	$60
Nov-24-20	Initiated	Morgan Stanley	Overweight	$49
Nov-24-20	Initiated	JP Morgan	Overweight	$45

Dec-05-24 07:06AM	Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir (TipRanks) -5.94%
Dec-04-24 03:14PM	After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study (Benzinga) -10.49%
07:00AM	Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV) (GlobeNewswire)
06:09AM	Atea plans Phase 3 study for hepatitis C drug after mid-stage results (BioPharma Dive)
Nov-26-24 07:00AM	Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
09:40AM	Loading…
Nov-22-24 09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-15-24 11:00AM	Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 (GlobeNewswire)
Nov-11-24 08:01PM	Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com)
Nov-07-24 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (GlobeNewswire)
Oct-30-24 07:00AM	Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 (GlobeNewswire)
Oct-16-24 09:40AM	Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? (Zacks) +6.20%
Oct-09-24 05:19PM	Atea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
Oct-04-24 09:35AM	Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-30-24 09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
02:53PM	Loading…
Sep-13-24 02:53PM	Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus (Benzinga) +5.45%
07:00AM	Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 (GlobeNewswire)
Aug-28-24 09:40AM	Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? (Zacks)
07:00AM	Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway (GlobeNewswire)
Aug-12-24 12:00PM	All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy (Zacks)
09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-07-24 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +7.03%
Jul-31-24 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 (GlobeNewswire)
Jun-05-24 07:00AM	Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 (GlobeNewswire) +5.04%
May-29-24 07:00AM	Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-22-24 07:00AM	Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 (GlobeNewswire) +5.82%
May-15-24 09:01AM	Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ... (GuruFocus.com) -6.31%
May-14-24 04:05PM	Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 07:00AM	Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024 (GlobeNewswire)
Apr-29-24 07:00AM	Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 (GlobeNewswire)
07:00AM	Loading…
Mar-27-24 07:00AM	Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients (GlobeNewswire) +6.10%
Feb-29-24 10:03AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:58PM	Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-21-24 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 (GlobeNewswire)
Jan-10-24 09:30AM	Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study (Zacks)
Jan-08-24 04:05PM	Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19 (GlobeNewswire) +11.29%
Jan-03-24 07:00AM	Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-13-23 07:00AM	Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 03:57PM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript (Insider Monkey) -9.12%
05:48AM	Q3 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Nov-02-23 07:00AM	Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-01-23 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023 (GlobeNewswire) -5.23%
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Sep-06-23 07:00AM	Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-09-23 06:58AM	Q2 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023 (GlobeNewswire)
Jun-15-23 07:00AM	Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination (GlobeNewswire)
Jun-05-23 04:20PM	Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 07:00AM	Atea Pharmaceuticals Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners Affiliate, Concentra Biosciences (GlobeNewswire) -11.97%
May-26-23 07:02PM	Lordstown Motors and Atea Pharmaceuticals Stock See Action From Activist Investors (Barrons.com)
May-23-23 04:05PM	Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners Affiliate, Concentra Biosciences (GlobeNewswire)
May-10-23 11:53AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-09-23 10:09AM	Q1 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 04:05PM	Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-01-23 04:05PM	Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023 (GlobeNewswire)
Apr-25-23 07:00AM	Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19 (GlobeNewswire)
Apr-12-23 07:00AM	Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases (GlobeNewswire)
Mar-14-23 07:00AM	New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research (GlobeNewswire) +7.72%
Mar-08-23 07:00AM	New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research (GlobeNewswire)
Mar-02-23 09:20PM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2022 Earnings Call Transcript (Insider Monkey) +5.54%
Feb-28-23 04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) -8.19%
Feb-23-23 07:00AM	Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023 (GlobeNewswire)
Feb-21-23 07:00AM	Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023 (GlobeNewswire) -5.41%
Feb-15-23 04:05PM	Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections (GlobeNewswire)
Feb-13-23 08:22AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is a favorite amongst institutional investors who own 62% (Simply Wall St.)
Feb-07-23 07:00AM	Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-09-23 07:00AM	Atea Pharmaceuticals Highlights Strategic Priorities for 2023 (GlobeNewswire)
Jan-04-23 07:00AM	Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-22 11:10AM	Boston biotech retools Covid drug to make 'next generation of Paxlovid' (American City Business Journals) +5.01%
Nov-29-22 07:00AM	Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19 (GlobeNewswire)
Nov-22-22 07:00AM	Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-19-22 09:46AM	Atea Pharmaceuticals (NASDAQ:AVIR) shareholders have endured a 42% loss from investing in the stock a year ago (Simply Wall St.)
Nov-10-22 12:00PM	Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade (Zacks) +7.59%
09:35AM	After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR) (Zacks)
Nov-08-22 04:05PM	Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -9.88% -10.40%
Nov-07-22 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-22 08:36AM	Why Atea Pharmaceuticals (AVIR) Might Surprise This Earnings Season (Zacks)
Nov-03-22 07:00AM	Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting (GlobeNewswire)
Nov-02-22 11:14AM	Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates (Zacks)
Oct-31-22 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022 (GlobeNewswire)
Oct-18-22 10:58AM	One Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) insider upped their stake by 106% in the previous year (Simply Wall St.)
Sep-27-22 09:53AM	Atea (AVIR) Dengue Candidate Gets Fast Track Designation (Zacks)
Sep-26-22 09:33AM	Atea Pharma's Investigational Dengue Treatment Fast Tracked In US (Benzinga) -5.17%
07:00AM	Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue (GlobeNewswire)
Sep-13-22 09:56AM	Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir (Benzinga) -10.15%
07:00AM	Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 (GlobeNewswire)
Sep-07-22 07:00AM	Atea Pharmaceuticals Announces Upcoming Investor Events (GlobeNewswire)
Sep-06-22 08:18AM	With 62% ownership of the shares, Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is heavily dominated by institutional owners (Simply Wall St.)
Aug-09-22 06:00AM	Atea Pharmaceuticals, Inc. (AVIR) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-08-22 04:30PM	Edited Transcript of AVIR.OQ earnings conference call or presentation 8-Aug-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-22 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022 (GlobeNewswire)
Jul-13-22 12:00PM	Atea Pharmaceuticals, Inc. (AVIR) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Jul-11-22 07:00AM	Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference (GlobeNewswire)
Jul-07-22 08:45AM	Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? (Simply Wall St.)
Jul-02-22 10:23AM	Use This 1 Genius Trick for Finding Dirt Cheap Biotech Stocks in the Bear Market (Motley Fool)

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BERGER FRANKLIN M	Director	Dec 10 '24	Sale	2.85	359,606	1,023,475	451,897	Dec 12 06:00 PM
Franklin Berger	Lead Independent Director	Dec 10 '24	Proposed Sale	2.85	359,606	1,023,475		Dec 10 05:17 PM
Sommadossi Jean-Pierre	President, CEO, and Chairman	Sep 17 '24	Sale	4.05	33,941	137,318	5,890,053	Sep 19 08:02 PM
Sommadossi Jean-Pierre	President, CEO, and Chairman	Sep 18 '24	Sale	4.03	22,187	89,469	5,867,866	Sep 19 08:02 PM
Sommadossi Jean-Pierre	President, CEO, and Chairman	Sep 19 '24	Sale	4.00	1,841	7,367	5,866,025	Sep 19 08:02 PM
JPM Partners LLC	Affiliate	Sep 19 '24	Proposed Sale	4.00	1,841	7,367		Sep 19 04:22 PM
JPM Partners LLC	Affiliate	Sep 18 '24	Proposed Sale	4.03	22,187	89,469		Sep 18 04:09 PM
JPM Partners LLC	Affiliate	Sep 17 '24	Proposed Sale	4.05	33,941	137,318		Sep 17 04:16 PM
Polsky Bruce	Director	Jun 20 '24	Sale	3.49	17,544	61,144	65,606	Jun 21 05:59 PM
Murphy Polly A.	Director	Jun 16 '24	Option Exercise	0.00	33,150	0	56,445	Jun 18 05:00 PM
Lucidi Bruno	Director	Jun 16 '24	Option Exercise	0.00	33,150	0	83,150	Jun 18 05:00 PM
BERGER FRANKLIN M	Director	Jun 16 '24	Option Exercise	0.00	33,150	0	811,503	Jun 18 05:00 PM
Polsky Bruce	Director	Jun 16 '24	Option Exercise	0.00	33,150	0	83,150	Jun 18 05:00 PM
Duncan Barbara Gayle	Director	Jun 16 '24	Option Exercise	0.00	33,150	0	33,150	Jun 18 05:00 PM
Adams Jerome M.	Director	Jun 16 '24	Option Exercise	0.00	33,150	0	33,150	Jun 18 05:00 PM
Sommadossi Jean-Pierre	President, CEO, and Chairman	Jun 05 '24	Sale	4.00	1,006	4,024	5,923,994	Jun 07 06:34 PM
Corcoran Andrea	See Remarks	Feb 01 '24	Sale	3.84	15,843	60,915	670,208	Feb 02 09:31 PM
Sommadossi Jean-Pierre	President, CEO, and Chairman	Feb 01 '24	Sale	3.85	56,910	218,819	116,557	Feb 02 09:30 PM
Horga Maria Arantxa	Chief Medical Officer	Feb 01 '24	Sale	3.84	15,870	60,963	25,664	Feb 02 09:29 PM
Foster Wayne	EVP, Chief Accounting Officer	Feb 01 '24	Sale	3.84	12,477	47,904	20,857	Feb 02 09:26 PM
Vavricka John	Chief Commercial Officer	Feb 01 '24	Sale	3.84	11,819	45,420	21,515	Feb 02 09:25 PM
Hammond Janet MJ	Chief Development Officer	Feb 01 '24	Sale	3.84	14,029	53,913	35,362	Feb 02 09:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVIR

Atea Pharmaceuticals Inc

Upgrade your FINVIZ experience